

## ALK-7 Protein, Human (HEK293, Fc)

|                   |  |
|-------------------|--|
| Cat. No.:         | HY-P74417  |
| Synonyms:         | Activin receptor type IC; ACTR-IC; ACVRLK7; ALK7 |
| Species:          | Human  |
| Source:           | HEK293   |
| Accession:        | Q8NER5 (L22-E113)                                |
| Gene ID:          | 130399   |
| Molecular Weight: | Approximately 36.6-56 kDa                        |

### PROPERTIES

|                     |  |
|---------------------|--|
| AA Sequence         | <div> <div>L S P G L K C V C L</div> <div>L C D S S N F T C Q</div> <div>T E G A C W A S V M</div> <div>L T N G K E Q V I K</div> <div>S C V S L P E L N A</div> <div>Q V F C H S S N N V</div> <div>T K T E C C F T D F</div> <div>C N N I T L H L P T</div> <div>A S P N A P K L G P</div> <div>M E</div> </div> |
| Biological Activity | Measured by its binding ability in a functional ELISA. When Recombinant Human ALK-7 is immobilized at 2 µg/mL (100 µL/well) can bind Biotinylated Recombinant Human Nodal. The ED <sub>50</sub> for this effect is 243.4 ng/mL.  |
| Appearance          | Lyophilized powder   |
| Formulation         | Lyophilized from a 0.2 µm filtered solution of PBS, pH 7.4.  |
| Endotoxin Level     | <1 EU/µg, determined by LAL method.  |
| Reconstitution      | It is not recommended to reconstitute to a concentration less than 100 µg/mL in ddH <sub>2</sub> O. For long term storage it is recommended to add a carrier protein (0.1% BSA, 5% HSA, 10% FBS or 5% Trehalose).  |
| Storage & Stability | Stored at -20°C for 2 years. After reconstitution, it is stable at 4°C for 1 week or -20°C for longer (with carrier protein). It is recommended to freeze aliquots at -20°C or -80°C for extended storage.   |
| Shipping            | Room temperature in continental US; may vary elsewhere.  |

### DESCRIPTION

|            |  |
|------------|--|
| Background | <p>ALK-7, also known as ACVR1C, is a serine/threonine kinase consistent with the characteristics of a type-I receptor. ALK-7 is predominantly expressed in central nervous system. ALK-7 can form complexes with type II receptor serine-threonine kinases for TGF-β and activin in a ligand-dependent manner<sup>[1]</sup>.</p> <p>The ALK-7 gene encodes a 55-kDa cell-surface protein that exhibits up to 78% amino acid sequence identity in the kinase domain to previously isolated type I receptors for TGF-β and activin. In the extracellular domain, however, ALK-7 is more divergent, displaying comparable similarities with all members of the ALK subfamily. Originally identified and cloned from</p> |
|------------|--|

rat brain, ALK-7 mRNA is present throughout the digestive and central nervous system of rats. The function of ALK-7 as a type I receptor was confirmed with a constitutively activemutant form that activated a TGF- $\beta$ /activin response reporter. ALK-7 has also been found to activate some components of the Smad pathway, such as Smad2 and Smad3, in fetal and adult rat pancreas. In the rat pheochromocytoma PC12 cell line, ALK-7 not only activated both Smad2, Smad3, and the MAPK of extracellular signal-regulated kinase and JNK, but it inhibits cell proliferation as well. The human gene for ALK-7 has been mapped to the genetic location of 2q24.1-q3, with most of the mRNA located in the brain, pancreas, and colon. ALK-7 mediates high-ambient glucose-induced cardiomyoblasts apoptosis through the activation of Smad2/3<sup>[1][2][3]</sup>. ALK-7 combined with specific ligands, such as Nodal, activin B and growth differentiation factor (GDF), can activate Smads and other signaling pathways, thereby regulating cell proliferation, differentiation and apoptosis in various cells. Besides that, ALK-7, along with ALK-5 and ALK-6, participated in renal interstitial fibrosis<sup>[1][2][3]</sup>.

## REFERENCES

- [1]. M Rydén, et al. A novel type I receptor serine-threonine kinase predominantly expressed in the adult central nervous system. *J Biol Chem*. 1996 Nov 29;271(48):30603-9.
- [2]. Byung-Chul Kim, et al. Activin receptor-like kinase-7 induces apoptosis through activation of MAPKs in a Smad3-dependent mechanism in hepatoma cells. *J Biol Chem*. 2004 Jul 2;279(27):28458-65.
- [3]. Wen-bo Li, et al. Silencing of activin receptor-like kinase 7 alleviates aortic stiffness in type 2 diabetic rats. *Acta Diabetol*. 2015 Aug;52(4):717-26.
- [4]. Kunihiro Tsuchida, et al. Activin isoforms signal through type I receptor serine/threonine kinase ALK7. *Mol Cell Endocrinol*. 2004 May 31;220(1-2):59-65.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA